Key considerations in the treatment of complicated staphylococcal infections

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Rising antimicrobial resistance in Gram-positive pathogens, especially Staphylococcus aureus, threatens current treatments.
• Methicillin-resistant S. aureus (MRSA) rates have surged, alongside emerging vancomycin-intermediate (VISA, hVISA) and vancomycin-resistant (VRSA) strains.
• Vancomycin, the standard for MRSA, faces challenges due to increasing minimum inhibitory concentrations (MICs), poor tissue penetration, and tolerance, impacting treatment outcomes.

Purpose of the Study:

• To highlight the urgent need for novel antimicrobial agents against resistant Staphylococcus aureus strains.
• To emphasize the limitations of current therapies, particularly vancomycin, in treating serious Gram-positive bacterial infections.
• To advocate for the development of new drugs with potent bactericidal activity and improved susceptibility profiles.

Main Methods:

• Literature review of antimicrobial resistance trends in Staphylococcus aureus.
• Analysis of vancomycin efficacy and limitations against resistant strains (MRSA, VISA, hVISA, VRSA).
• Identification of criteria for new antimicrobial agents targeting staphylococcal infections.

Main Results:

• Significant increases in antimicrobial resistance among Gram-positive pathogens, particularly S. aureus.
• Emergence and spread of MRSA, VISA, hVISA, and VRSA strains limit therapeutic options.
• Vancomycin's efficacy is compromised by resistance, tolerance, increasing MICs, and suboptimal pharmacokinetic properties.

Conclusions:

• Existing treatments are increasingly ineffective against resistant Staphylococcus aureus strains.
• There is a critical need for new antimicrobial agents with potent bactericidal activity.
• Novel agents should exhibit superior susceptibility profiles compared to current glycopeptides to combat resistant staphylococcal infections.